Small‐Molecule Allosteric Inhibitors of Human Aspartate Transcarbamoylase Suppress Proliferation of Bone Osteosarcoma Epithelial Cells
ChemMedChem · 2024
DOI: 10.1002/cmdc.202300688 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2024. Verfasst von Chao Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: XB20 Drug Design, Groningen Research Institute of Pharmacy, University of Groningen, A. Deusinglaan 1, Groningen, 9700AV, The, Netherlands. Hauptthemen laut MEDLINE: Cell Proliferation, Osteosarcoma, Aspartate Carbamoyltransferase, Enzyme Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese Scholarship Council, ZonMw, SNSF Sinergia.
Abstract (Originalsprache)
Aspartate transcarbamoylase (ATC) is the first committed step in de novo pyrimidine biosynthesis in eukaryotes and plants. A potent transition state analog of human ATCase (PALA) has previously been assessed in clinical trials for the treatment of cancer, but was ultimately unsuccessful. Additionally, inhibition of this pathway has been proposed to be a target to suppress cell proliferation in E. coli , the malarial parasite and tuberculosis. In this manuscript we screened a 70‐member library of ATC inhibitors developed against the malarial and tubercular ATCases for inhibitors of the human ATC. Four compounds showed low nanomolar inhibition (IC 50 30–120 nM) in an in vitro activity assay. These compounds significantly outperform PALA, which has a triphasic inhibition response under identical conditions, in which significant activity remains at PALA concentrations above 10 μM. Evidence for a druggable allosteric pocket in human ATC is provided by both in vitro enzyme kinetic, homology modeling and in silico docking. These compounds also suppress the proliferation of U2OS osteoblastoma cells by promoting cell cycle arrest in G0/G1 phase. This report provides the first evidence for an allosteric pocket in human ATC, which greatly enhances its druggability and demonstrates the potential of this series in cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- XB20 Drug Design, Groningen Research Institute of Pharmacy, University of Groningen, A. Deusinglaan 1, Groningen, 9700AV, The, Netherlands.
- Department of Biomedicine, Aarhus University, Ole Worms Alle' 4, 8000, Aarhus C, Denmark.
- Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, 9700 RB, Groningen, The, Netherlands.
- CATRIN, Department of Innovative Chemistry, Palack University, 779 00, Olomouc - Holice, Czech Republic.
ORCID-Profile: Chao Wang, Bidong Zhang, Siyao Chen, Lidia Visser, Angel J Ruiz-Moreno, Lili Zhang, Fulvio Reggiori, Alexander S S Dömling, Matthew R Groves
Förderung
- Chinese Scholarship Council
- ZonMw
- SNSF Sinergia
- NWO Veni
- Novo Nordisk Foundation
- Novo Nordisk Fonden
Zitieren
APA
Wang, C., Zhang, B., Cong, Y., Du, X., Chen, S., Visser, L., Ruiz-Moreno, A. J., Zhang, L., Reggiori, F., Dömling, A. S. S., & Groves, M. R. (2024). Small‐Molecule Allosteric Inhibitors of Human Aspartate Transcarbamoylase Suppress Proliferation of Bone Osteosarcoma Epithelial Cells. ChemMedChem. https://doi.org/10.1002/cmdc.202300688
Vancouver
Wang C, Zhang B, Cong Y, Du X, Chen S, Visser L, et al. Small‐Molecule Allosteric Inhibitors of Human Aspartate Transcarbamoylase Suppress Proliferation of Bone Osteosarcoma Epithelial Cells. ChemMedChem. 2024. doi:10.1002/cmdc.202300688
BibTeX
@article{Wang2024,
author = {Wang, Chao and Zhang, Bidong and Cong, Yingying and Du, Xiaochen and Chen, Siyao and Visser, Lidia and Ruiz-Moreno, Angel J and Zhang, Lili and Reggiori, Fulvio and Dömling, Alexander S S and Groves, Matthew R},
title = {Small‐Molecule Allosteric Inhibitors of Human Aspartate Transcarbamoylase Suppress Proliferation of Bone Osteosarcoma Epithelial Cells},
journal = {ChemMedChem},
year = {2024},
doi = {10.1002/cmdc.202300688}
}
EUVIMED